KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Assets Average (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Assets Average readings, the most recent being $415.0 million for Q4 2025.

  • On a quarterly basis, Assets Average rose 26.14% to $415.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $415.0 million, a 26.14% increase, with the full-year FY2025 number at $404.9 million, up 47.32% from a year prior.
  • Assets Average hit $415.0 million in Q4 2025 for Esperion Therapeutics, up from $355.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $415.0 million in Q4 2025 to a low of $213.6 million in Q4 2023.
  • Median Assets Average over the past 5 years was $312.2 million (2021), compared with a mean of $305.8 million.
  • Biggest five-year swings in Assets Average: surged 60.34% in 2021 and later crashed 31.01% in 2023.
  • Esperion Therapeutics' Assets Average stood at $303.4 million in 2021, then fell by 7.59% to $280.4 million in 2022, then fell by 23.84% to $213.6 million in 2023, then surged by 54.05% to $329.0 million in 2024, then increased by 26.14% to $415.0 million in 2025.
  • The last three reported values for Assets Average were $415.0 million (Q4 2025), $355.6 million (Q3 2025), and $335.6 million (Q2 2025) per Business Quant data.